MYCxing it up with FGFR1 in squamous cell lung cancer

William Lockwood; Katerina Politi

doi:10.1158/2159-8290.CD-13-1049

MYCxing it up with FGFR1 in squamous cell lung cancer

Cancer Discov. 2014 Feb;4(2):152-4. doi: 10.1158/2159-8290.CD-13-1049.

Authors

William Lockwood¹, Katerina Politi

Affiliation

¹ 1Cancer Biology and Genetics Section, Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland; and 2Departments of Pathology and Medicine (Medical Oncology), Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.

Abstract

Recurrent amplification of 8p12 is observed in squamous cell lung cancer, and FGFR1 is thought to be the main oncogenic driver in this region. In this issue of Cancer Discovery, Malchers and colleagues perform a detailed characterization of 8p12 in squamous cell lung cancer and find remarkable genomic heterogeneity in this region, raising the possibility that other genes in addition to FGFR1 may play a role in squamous cell lung cancer. Mechanistic studies of the FGFR1-amplified subset of squamous cell lung cancer reveal potential roles for fibroblast growth factor (FGF) ligands and MYC expression levels in modulating the response of these tumors to FGF receptor inhibition.

2014 AACR

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Cell Transformation, Neoplastic / genetics*
Gene Amplification*
Humans
Lung Neoplasms / genetics*
Receptor, Fibroblast Growth Factor, Type 1 / genetics*

Substances

Receptor, Fibroblast Growth Factor, Type 1

Abstract

Publication types

MeSH terms

Substances

Grants and funding